Metoclopramide Rompharm 5 mg/ml solution for injection

Therapeutic indications

Adult population:

Metoclopramide Rompharm 5 mg/ml solution for injection is indicated in adults for: 

- revention of post operative nausea and vomiting (PONV); 

- symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting; 

- prevention of radiotherapy induced nausea and vomiting (RINV).

Paediatric population

{Invented name} 5 mg/ml solution for injection is indicated in children aged 1-18 years for: 

- prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second-line option; 

- treatment of postoperative nausea and vomiting (PONV) as a second-line option.

Metoclopramide stimulates and coordinates the motility of the upper gastrointestinal tract, without altering gastric, pancreatic and biliary secretion. 

Its mechanism of action is complex, the drug being a competitive antagonist of D1 and D2 (dopamine) receptors and 5-HT3 (serotonin) receptors, as well as a nonspecific agonist of 5-HT4 receptors involved in the stimulation of enteric cholinergic neurons. It thus has intestinal prokinetic activity, independent of vagal innervation but abolished by atropine and other muscarinic antagonists. 

It causes an increase in the tone and amplitude of gastroduodenal contractions and, to a progressively reduced extent distally, a coordinated increase in the propulsive movements of the jejunum, ileum, and colon, with a peripheral progression of endoluminal contents. 

It still increases the tone of the musculature of the middle and lower third of the esophagus and thus the pressure at the level of the sphincter, while releasing pylorus and duodenal bulb. These actions result in accelerated gastric emptying and decreased reflux from the duodenum into the stomach and esophagus.